MARCATOR

MARCATOR

Multicenter American Research trial with Cilazapril after Angioplasty to prevent Transluminal coronary Obstruction and Restenosis. A clinical trial that evaluated ACE inhibition for preventing restenosis after PCTA in patients with CAD.

Conclusion
Long-term ACE inhibition by cilazapril neither prevented restenosis nor reduced post-PCTA cardiac events.

MARCATOR

Cardiology A clinical trial–Multicenter American Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction & Restenosis that evaluated ACE inhibition in preventing restenosis after PCTA in Pts with CAD. See Coronary artery disease, Percutaneous transluminal angioplasty.
Mentioned in ?
References in periodicals archive ?
MARCATOR grubu 1400 hastada calismis ve silazapril altinci ayin sonunda restenoza etki etmeyerek basarisizli kla sonuclanmis (26).